Literature DB >> 16794368

Persistent and moderate hypercalcemia related to an ovarian clear cell adenocarcinoma: Pre- and postoperative parathyroid hormone related-peptide and 1,25-dihydroxyvitamin D3 levels.

A Benit1, J Allard, J Rimailho, J Fauvel, G Escourrou, D Vezzosi, F Donadille, A Bennet, P Caron.   

Abstract

OBJECTIVE: To evaluate the role of PTH-related peptide (PTH-rP) and 1,25-dihyhydroxyvitamin D3 in a case of hypercalcemia related to an ovarian adenocarcinoma.
DESIGN: We report a case of humoral hypercalcemia in a patient aged 74 yr with a clear cell adenocarcinoma of the right ovary at an early stage of its development (stage T1aN0M0) revealed by moderate and persistent hypercalcemia (variable level between 2.7 and 3.2 mmol/l without any treatment) over six months.
METHODS: PTH-rP and 1,25-dihydroxyvitamin D3 were measured in blood samples taken before and after hysterectomy and bilateral salpingooophorectomy and in blood samples taken intraoperatively from the right ovarian vein and a peripheral vein.
RESULTS: High levels of plasma PTH-rP and 1,25-dihydroxyvitamin D3 concomitant with high serum calcium and low PTH levels were found before surgery, which was followed by normalisation of all parameters studied. A concentration gradient was found regarding plasma PTHrP (right ovarian vein 60.4 pmol/l, peripheral vein 4.5 pmol/l), not 1,25-dihydroxyvitamin D3.
CONCLUSION: 1) moderate and persistent hypercalcemia can be observed at an early stage of an ovarian carcinoma; 2) the gradient of PTH-rP concentration between the samples taken from the right ovarian vein and a peripheral vein provides evidence for a direct secretion of PTH-rP by the ovarian tumor; 3) the increased 1,25-dihydroxyvitamin D3 level is not related to a direct ovarian production, but is a consequence of PTH-rP secretion.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16794368     DOI: 10.1007/BF03344128

Source DB:  PubMed          Journal:  J Endocrinol Invest        ISSN: 0391-4097            Impact factor:   4.256


  45 in total

1.  Hypercalcemia due to parathyroid hormone-related protein produced by primary ovarian clear cell adenocarcinoma: case report.

Authors:  R Tsunematsu; T Saito; H Iguchi; T Fukuda; N Tsukamoto
Journal:  Gynecol Oncol       Date:  2000-02       Impact factor: 5.482

2.  Expression of parathyroid hormone-related peptide (PTH-rp) and its receptorin the porcine ovary: regulation by transforming growth factor-beta and possible paracrine effects of granulosa cell PTH-rp secretion on theca cells.

Authors:  J C Garmey; J A Schnorr; M E Bruns; D E Bruns; R M Seaner; J E Ferguson II; F C Luking Jayes; C Aguirre; J D Veldhuis
Journal:  Biol Reprod       Date:  2000-02       Impact factor: 4.285

3.  Parathyroid hormone-like peptide in normal and neoplastic human endocrine tissues.

Authors:  S L Asa; J Henderson; D Goltzman; D J Drucker
Journal:  J Clin Endocrinol Metab       Date:  1990-11       Impact factor: 5.958

4.  Biochemical evaluation of patients with cancer-associated hypercalcemia: evidence for humoral and nonhumoral groups.

Authors:  A F Stewart; R Horst; L J Deftos; E C Cadman; R Lang; A E Broadus
Journal:  N Engl J Med       Date:  1980-12-11       Impact factor: 91.245

5.  The role of 1,25-dihydroxyvitamin D in the maintenance of hypercalcemia in a patient with an ovarian carcinoma producing parathyroid hormone-related protein.

Authors:  K Hoekman; Y I Tjandra; S E Papapoulos
Journal:  Cancer       Date:  1991-08-01       Impact factor: 6.860

6.  Conflicting actions of parathyroid hormone-related protein and serum calcium as regulators of 25-hydroxyvitamin D(3)-1 alpha-hydroxylase expression in a nude rat model of humoral hypercalcemia of malignancy.

Authors:  T Michigami; H Yamato; H Suzuki; Y Nagai-Itagaki; K Sato; K Ozono
Journal:  J Endocrinol       Date:  2001-11       Impact factor: 4.286

7.  Suppression of serum 1,25-dihydroxyvitamin D in humoral hypercalcemia of malignancy is caused by elaboration of a factor that inhibits renal 1,25-dihydroxyvitamin D3 production.

Authors:  S Fukumoto; T Matsumoto; H Yamoto; H Kawashima; Y Ueyama; N Tamaoki; E Ogata
Journal:  Endocrinology       Date:  1989-05       Impact factor: 4.736

8.  Increased expression of 25-hydroxyvitamin D-1alpha-hydroxylase in dysgerminomas: a novel form of humoral hypercalcemia of malignancy.

Authors:  Katie N Evans; Harris Taylor; Daniel Zehnder; Mark D Kilby; Judith N Bulmer; Farah Shah; John S Adams; Martin Hewison
Journal:  Am J Pathol       Date:  2004-09       Impact factor: 4.307

9.  An immunohistochemical analysis of ovarian small cell carcinoma of hypercalcemic type.

Authors:  W G McCluggage; E Oliva; L E Connolly; H A McBride; R H Young
Journal:  Int J Gynecol Pathol       Date:  2004-10       Impact factor: 2.762

10.  A case of pheochromocytoma producing parathyroid hormone-related protein and presenting with hypercalcemia.

Authors:  S Kimura; Y Nishimura; K Yamaguchi; K Nagasaki; K Shimada; H Uchida
Journal:  J Clin Endocrinol Metab       Date:  1990-06       Impact factor: 5.958

View more
  1 in total

1.  Hypercalcemia of Malignancy and Colorectal Cancer.

Authors:  Rodolfo J Galindo; Isabela Romao; Ageliki Valsamis; Stuart Weinerman; Yael Tobi Harris
Journal:  World J Oncol       Date:  2016-02
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.